View Article Online View Journal

Organic & Biomolecular Chemistry

Accepted Manuscript

This article can be cited before page numbers have been issued, to do this please use: R. Yan and Z. Wang, *Org. Biomol. Chem.*, 2018, DOI: 10.1039/C8OB00723C.



This is an Accepted Manuscript, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this Accepted Manuscript with the edited and formatted Advance Article as soon as it is available.

You can find more information about Accepted Manuscripts in the **author guidelines**.

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard <u>Terms & Conditions</u> and the ethical guidelines, outlined in our <u>author and reviewer resource centre</u>, still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this Accepted Manuscript or any consequences arising from the use of any information it contains.



rsc.li/obc

ARTICLE



Organic & Biomolecular Chemistry Accepted Manuscript

Ruthenium-Catalyzed C–H Allylation of Arenes with Allylic Amines

Rui Yan^a and Zhong-Xia Wang^{*,a,b}

Received 00th January 20xx, Accepted 00th January 20xx

DOI: 10.1039/x0xx00000x

www.rsc.org/

The Ru-catalyzed pyridyl-directed C–H allylation of arenes with allylic amines has been developed. The reaction was carried out in the presence of 5 mol % of $[Ru(p-cymene)Cl_2]_2$ and 0.5 equiv. of AgOAc in CF₃CH₂OH at 75 °C, affording allylated products of arenes in moderate to excellent yields. The method exhibits a wide scope of allylic amines and arenes and shows good compatibility of functional groups. Pyrazolyl- and pyrimidyl-directed C–H allylation of arenes were also performed under the same conditions.

Introduction

The allyl group is a prominent structural motif found in many natural products and bioactive molecules. The compounds containing allyl moiety are also versatile building blocks in organic synthesis.¹ Therefore, allylation reactions have attracted much attention and a number of allylation methods have been developed.^{1,2} Allylic surrogates used in various allylation reactions include allylic halides,³ allylic alcohol⁴ or its derivatives,⁵ allenes,⁶ 1,3-dienes,⁷ and so on. Compared with above the allylation agents, allylic amines have rarely been employed due to the stability of the C-N bond.^{2g} However, it would be worthwhile to explore the reactions with allylic amines from the perspective of understanding their reactivity and finding novel allylation agents. Some successful trials have been carried out.^{8,9} For example, Trost and Spagnol developed a Ni-catalyzed cross-coupling of organoboronic acids with allylamines with high regioselectivity in 1995.^{9a} In 2007, List's group reported a highly enantioselective α -allylation of aldehydes catalyzed by palladium-based catalysts.^{9b} In 2011 Zhang et al. performed a Pd-catalyzed α -allylation of carbonyl compounds by reaction of allylic amines with ketones and aldehydes.^{9c} Recently Huang and co-workers reported a new method for the formation of β , γ -unsaturated amides by Pdcatalyzed carbonylation of allylamines via C-N bond activation. $^{9\text{d}}$ On the other hand, C–H activation and functionalization represent an atom-economic transformation. A series of C-H allylation reactions of unreactive systems by

Republic of China. E-mail: zxwang@ustc.edu.cn; Tel: 86 551 63603043 ^{b.} Collaborative Innovation Center of Chemical Science and Engineering, Tianjin

This journal is C The Royal Society of Chemistry 20xx

using allylic halides, allylic alcohols and their derivatives have been carried out.²⁻⁵ Inspired by previous work, we initiated a study of transition-metal-catalyzed allylation of arenes with allylic amines via C–H and C–N bond activation. Herein, we report the results.

Results and discussion

We commenced screening of reaction conditions by employing reaction of 2-phenylpyridine (1a) with N-allyl-N-methylaniline (2a) as the model reaction. The catalyst systems for Ni- or Pdcatalyzed allylic alkylation of carbonyl compounds were demonstrated to be ineffective to our reaction.9c,9e Ruthenium was reported to catalyze the C-H functionalization of arenes^{5a,10} and the C-N bond cleavage of allylic amines.¹¹ Hence we tried to use ruthenium complex $[Ru(p-cymene)Cl_2]_2$ as the catalyst. The reaction of 1a with 2 equiv. of 2a in MeOH at 75 °C in the presence of [Ru(p-cymene)Cl₂]₂ (5 mol %) and AgOAc (1.0 equiv.) resulted in a mixture of 3aa (26%) and 3aa' (16%) after 12 h (Table 1, entry 1). The positive result encouraged us to further examine the reaction in different solvents. The use of both EtOH and i-PrOH as solvents also led to positive results and the latter exhibited better selectivity (entries 2 and 3 in Table 1). However, use of aprotic solvents involving toluene, THF and DMF gave negative results (entries 4-6 in Table 1). This experimental fact might imply that the reaction was promoted via a hydrogen bond-assisted activation as that in Pd-catalyzed allylic alkylation of carbonyl compounds.^{9c} CF₃CH₂OH was found to be a better solvent than the alcohols mentioned above and the reaction in CF₃CH₂OH gave **3aa** in 52% yield (entry 7 in Table 1). (CF₃)₂CHOH exhibited poorer efficiency compared with CF₃CH₂OH. The reaction in (CF₃)₂CHOH led to a mixture of 3aa (40%) and 3aa' (10%) (entry 8 in Table 1). Hence the further condition screenings were performed in CF₃CH₂OH. Increasing loading of allylic amine markedly enhanced the product yield. Employing 4 equiv. of allylic amine gave excellent reaction result and

^{a.} CAS Key Laboratory of Soft Matter Chemistry and Department of Chemistry, University of Science and Technology of China, Hefei, Anhui 230026, People's

^{300072,} People's Republic of China.

⁺ Electronic Supplementary Information (ESI) available: Details of the mechanistic study and copies of NMR spectra of the cross-coupling products. This material is available free of charge via the Internet at http://pubs.acs.org. See DOI: 10.1039/x0xx00000x

Published on 07 May 2018. Downloaded by Kaohsiung Medical University on 07/05/2018 11:41:20

Table 1 Optimization of reaction conditions^a



| Entry | Base (equiv.) | 2a (equiv.) | solvent | yield (%) ^b 3aa (3aa') |
|-----------------|-------------------------|--------------------|------------------------------------|--------------------------------------|
| 1 | AgOAc (1) | 2 | MeOH | 26 (16) |
| 2 | AgOAc (1) | 2 | EtOH | 16 (26) |
| 3 | AgOAc (1) | 2 | <i>i</i> -PrOH | 29 (0) |
| 4 | AgOAc (1) | 2 | Toluene | - |
| 5 | AgOAc (1) | 2 | THF | - |
| 6 | AgOAc (1) | 2 | DMF | - |
| 7 | AgOAc (1) | 2 | CF_3CH_2OH | 52 (0) |
| 8 | AgOAc (1) | 2 | (CF ₃)₂CHOH | 40 (10) |
| 9 | AgOAc (1) | 3 | CF ₃ CH ₂ OH | 80 (0) |
| 10 | AgOAc (1) | 4 | CF_3CH_2OH | 86 (0) |
| 11 | AgOAc (1) | 5 | CF ₃ CH ₂ OH | 88 (0) |
| 12 ^c | AgOAc (1) | 4 | CF_3CH_2OH | 78 (14) |
| 13 ^d | AgOAc (1) | 4 | CF_3CH_2OH | 74 (0) |
| 14 ^e | AgOAc (1) | 4 | CF ₃ CH ₂ OH | 85 (0) |
| 15 | AgOAc (1.5) | 4 | CF_3CH_2OH | 80 (0) |
| 16 | AgOAc (0.5) | 4 | CF_3CH_2OH | 90 (0) |
| 17 | AgOAc (0.2) | 4 | CF ₃ CH ₂ OH | 79 (0) |
| 18 ^f | AgOAc (0.5) | 4 | CF_3CH_2OH | 91 (0) |
| 19 ^g | AgOAc (0.5) | 4 | CF ₃ CH ₂ OH | 83 (0) |
| 20 | KOAc (1) | 4 | CF ₃ CH ₂ OH | 81 (0) |
| 21 | AgOTf (0.5) | 4 | CF_3CH_2OH | 8 (30) |
| 22 | Ag ₂ O (0.5) | 4 | CF ₃ CH ₂ OH | 3 (41) |
| 23 | AgF (0.5) | 4 | CF₃CH₂OH | 7 (29) |
| 24 | none | 4 | CF_3CH_2OH | 5 (35) |
| 25 ^h | AgOAc (0.5) | 4 | CF ₃ CH ₂ OH | - |
| 26 ⁱ | AgOAc (0.5) | 4 | CF_3CH_2OH | 88 (0) |

^a Unless otherwise specified, the reactions were carried out on a 0.2 mmol scale according to the conditions indicated by above equation. ^b Isolated yield. ^c 2.5 mol % [Ru(*p*-cymene)Cl₂]₂ was employed. ^d Reaction time was 6 h. ^e Reaction time was 24 h. ^f Reaction was run at 100 °C. ^g Reaction was run at 50 °C. ^h No [Ru(*p*-cymene)Cl₂]₂ was employed. ⁱ The reaction was on a 4 mmol scale.

higher loading of allylic amine did not markedly increase the product yield (entries 9-11 in Table 1). Lowering the amount of $[Ru(p-cymene)Cl_2]_2$ to 2.5 mol % resulted in decrease of **3aa** yield along with formation of **3aa'** in 14% yield (entry 12 in Table 1). If the reaction time was shortened to 6 h the yield of **3aa** decreased to 74%. However, extending reaction time to 24 h did not increase the product yield (entries 13 and 14 in Table 1). Next, we examined the effect of AgOAc dosage and found

0.5 equiv of AgOAc loading was optimal (entries 15-17 in Table 1). The effect of temperature was next tested. Higher temperature than 75 °C did not enhance the product yield and lower temperature than 75 °C led to decrease of the yield (entries 18 and 19 in Table 1). Other bases including KOAc, AgOTf, Ag₂O, and AgF were also tested (entries 20-23 in Table 1). KOAc was a good base but less effective than AgOAc. AgOTf, Ag₂O, and AgF led to a mixture of 3aa and 3aa' in relatively low yields. In the absence of a base the reaction still occurred and gave a mixture of 3aa (5%) and 3aa' (35%) in relatively low overall yield (entry 24 in Table 1). In the absence of a Ru catalyst the reaction cannot occur (entry 25 in Table 1). Other Ru complexes including $RuH_2(CO)(PPh_3)_3$, $Cp*Ru(PPh_3)_2Cl$, $[Cp*RuCl]_4$ and $RuCl_2(PPh_3)_3$ were also noneffective or less effective than [Ru(p-cymene)Cl₂]₂ (Table S1 in the ESI). Finally, the optimized conditions were demonstrated to suit for the reaction with a larger scale of substrates. 0.4 Mmol of 1a was treated with 4 equiv. of 2a under the optimized conditions to afford 3aa in 88% yield (entry 26 in Table 1).

Next, we examined reaction of 2-phenylpyridine (1a) or 2-(o-tolyl)pyridine (1b) with different allylic amines under the optimized conditions and the results are listed in Table 2. N-Allyl-N-phenylaniline and N-allyl-N-phenylhydroxylamine reacted with 1a to afford 2-(2,6-diallylphenyl)pyridine (3aa) in 72% and 38% yield, respectively (entries 2 and 3 in Table 2). Reaction of 2-(o-tolyl)pyridine (1b) with various allylic amines resulted in ortho-monoallylation species. In this case 2 equiv. of allylic amine was enough to complete the reaction. N-Allyl-N-methylaniline still exhibited good reactivity. Its reaction with 1b gave 2-(2-allyl-6-methylphenyl)pyridine (3ba) in 88% yield (entry 4 in Table 2). Other phenyl allylamines including N-allyl-N-phenylaniline, N-allyl-N-phenylhydroxylamine, N,O-diallyl-N-phenylhydroxylamine, N-allylaniline, and N,N-diallylaniline reacted smoothly with 1b to form 3ba in 63%-92% yields (entries 5-9 in Table 2). It is noteworthy that N-allylaniline showed excellent reactivity in this transformation. Aliphatic allylic amines can also be used in this transformation. Reaction of 4-allylmorpholine with 1b at 50 °C afforded 3ba in 73% yield, which was higher than that obtained from the reaction at 75 °C (entry 10 in Table 2). Reaction of 1b with either N-(but-3-en-2-yl)-N-methylaniline or (E)-N-(but-2-en-1-yl)-Nmethyl-aniline gave high overall yields. But in each case a mixture of regio- and geo-isomers was obtained (entries 11 and 12 in Table 2).

To further examine the versatility of the reaction, we evaluated the scope of 2-arylpyridines using N-allyl-N-methylaniline (**2a**) as the allylation reagent. The results are summarized in Schemes 1 and 2, respectively. Compound **2a** reacted smoothly with electron-poor 2-arylpyridines including $2-(2-FC_6H_4)C_5H_4N$, $2-(2,4-F_2C_6H_3)C_5H_4N$, $2-(2-CIC_6H_4)C_5H_4N$, $2-(2-CF_3C_6H_4)C_5H_4N$ to give the corresponding monoallylation products (**3ca**-**3ga**, Scheme 1) in moderate to good yields. Among the substrates $2-(2-CIC_6H_4)C_5H_4N$ showed higher reactivity. Both $2-(2-FC_6H_4)C_5H_4N$ and $2-(2,4-F_2C_6H_3)C_5H_4N$ displayed relatively low reactivity.

Published on 07 May 2018. Downloaded by Kaohsiung Medical University on 07/05/2018 11:41:20

Journal Name

Part of the substrates remained unchanged. Under stronger conditions, reaction of $2-(2,4-F_2C_6H_3)C_5H_4N$ got improved to



^a Unless otherwise specified, the reactions were carried out on a 0.2 mmol scale according to the conditions indicated by above equation, 2 equiv. of allylic amines were employed. ^b Isolated yield. ^c 4 equiv. of allylic amines were employed. ^d The reaction was run at 50 °C. ^e Yield of the mixture.

some extent. 2-*m*-Tolylpyridine, 2-(3,4-dimethylphenyl) pyridine, and 2-(biphenyl-3-yl)pyridine occurred *ortho*-C-H monoallylation at the less hindered sites even in the presence

of excess allylic amine, affording the corresponding products in moderate yields (**3ha-3ja**, Scheme 1). Some starting materials



Scheme 1 Monoallylation of of 2-arylpyridines.^a Unless otherwise specified, the reactions were carried out on a 0.2 mmol scale according to the conditions indicated by the above equation, 2 equiv. of allylic amines were employed. ^b Yields of isolated products are reported. ^c 4 Equiv. of allylic amines were employed. ^d The reaction was run at 100 °C for 18 h in the presence of 7.5 mol % $[Ru(p-cymene)Cl_2]_2$.

remained unchanged. Both 2-(naphthalen-2-yl)pyridine and 2-(naphthalen-1-yl)pyridine also respectively reacted with **2a** under the standard conditions. The former gave monoallylation product 2-(3-allylnaphthalen-2-yl)pyridine (**3ka**, Scheme 1) in 51% yield, and the latter led to 2-(2allylnaphthalen-1-yl)pyridine (**3la**, Scheme 1) in 85% yield.

Reaction of the 2-(4-substituted phenyl)pyridines with 2a under the standard conditions resulted in bisallylation products (3ma-3wa, Scheme 2). The para-substituents included electron-donor groups such as Me, Ph, OMe, and OH and electron-withdrawing groups such as F, Cl, Br, COOEt, COOH, CF₃ and NO₂. Reaction of the substrates except 2-(4nitrophenyl)pyridine gave good yields. It seems that the reactivity of the substrates is uncorrelated with the electron effect of the substituents at the para position of the phenyl rings. However, reaction of 2-(4-nitrophenyl)pyridine gave relatively low product yield (45%) for unclear reasons. Surprisingly, respective reaction of 2-(3-methoxyphenyl)pyridine, 2-(3-fluorophenyl)pyridine and 2-(3-chlorophenyl)pyridine with 2a afforded bis-allylation products (3xa-3za, Scheme 2) in moderate to good yields. This is probably due to relatively small hindrance of these groups on the phenyl rings.

In addition, the catalyst system also suited for the bisallylation of arenes with other directing groups such as pyrazolyl group and pyrimidyl group. For example, reaction of 1-phenyl-1H-pyrazole with **2a** under the standard conditions

DOI: 10.1039/C8OB00723C Journal Name

ARTICLE

gave 1-(2,6-diallylphenyl)-1H-pyrazole (**4**) in 69% yield. Reaction of 2-phenylpyrimidine with **2a** under the standard conditions afforded 2-(2,6-diallylphenyl)pyrimidine (**5**) in 78% yield (Scheme 3).



Scheme 2 Bisallylation of 2-arylpyridines. ^a The reactions were carried out on a 0.2 mmol scale according to the conditions indicated by above equation, 4 equiv. of allylic amines were employed. ^b Yields of isolated products are reported.





To probe the reaction mechanism, we made the following experiments. Reaction of $[Ru(p-cymene)Cl_2]_2$ with 10 equiv. of

2-phenylpyridine in the presense of AgOAc (0.5 equiv.) in CF₃CH₂OH at 60 °C for 6 hours yielded ruthenium(II) complex 6 (a in Scheme 4). Structure of the complex was confirmed by comparing its spectroscopic data with those reported in literature.¹² No reaction occurred between [Ru(p-cymene)Cl₂]₂ and N-allyl-N-methylaniline under the same conditions. Complex 6 was demonstrated to react with 4 equiv. of N-allyl-N-methylaniline in the presence of AgOAc (0.5 equiv.) to afford 3aa in 29% yield (b in Scheme 4). Complex 6 was also demonstrated to catalyze reaction of 1a or 1b with 2a under the optimized conditions to give the corresponding products in similar yields to those employing [Ru(p-cymene)Cl₂]₂ as the catalyst (c in Scheme 4 and section 3.3 in the ESI). These experimental facts suggest that the cyclometalated complex could be an intermediate in the catalytic cycle. Furthermore, we measured the kinetic isotopic effect via reaction of 1a and **1a**-D5 with **2a** under the standard conditions. A k_H/k_D value of 1.1 was obtained by analyzing ¹H NMR spectrum of the product (d in Scheme 4). This result suggests that the C-Hbond cleavage may not be the rate-limiting step. As mentioned earlier, reaction of 2-(o-tolyl)pyridine with either N-(but-3-en-2-yl)-N-methylaniline or (E)-N-(but-2-en-1-yl)-N-methylaniline resulted in a mixture of regio- and geo-isomers (entries 11 and 12 in Table 2). This experimental fact implies that an η^3 allylruthenium intermediate is present in the catalytic cycle. The almost same distribution ratios of the products in the two reactions further proved that the same η^3 -allylruthenium intermediates were formed. In addition, the catalytic reaction cannot occur in the aprotic solvents such as toluene, THF and DMF but proceeded in alcohols including MeOH, EtOH, iPrOH, (CF₃)₂CHOH and CF₃CH₂OH (Table 1). We surmised that the protic solvents promote the C-N bond cleavage of allylic amines via a hydrogen-bond-activation.⁹⁰



Journal Name

On the basis of above experimental results and literature report,^{11a,13} we propose a plausible mechanism for the C–H allylation (Scheme 5). The formation of active catalyst **A** by action of [Ru(*p*-cymene)Cl₂]₂ with AgOAc. Coordination of the pyridine group of compound **1a** to **A** and then *ortho*-phenyl C–H bond activation form five-membered ring ruthenium intermediate **6**. Reaction of complex **6** with the hydrogenbond-activated **2a** affords an η^3 -allyl complex **B**. Reductive elimination of **B** results in **3aa'** and regenerates active catalyst **A** in the presence of OAc⁻. **3aa** is formed from **3aa'** via the same pathway as for **3aa'**.



Conclusions

In summary, a Ru-catalyzed method for allylation of arenes via cleavage of the C-N bond of allylic amines and pyridyl-directed aryl C-H activation has been developed. The reaction proceeded under mild conditions and afforded the allylation products in moderate to high yields. For 2-phenylpyridine and 2-(4-substituted phenyl)pyridines the reaction resulted in ortho-position bisallylation products of the phenyl groups. For the 2-(3-substituted phenyl)pyridines the reaction gave either monoallylation or bisallylation products depending on the steric hindrance of the 3-substituents. A range of functional groups including electron-withdrawing and electron-donor groups on the phenyl rings can be tolerated. Various allylamines including aromatic amines, aliphatic amines, and hydroxylamines were demonstrated to suit for this transformation. The reaction is proposed to proceed via a hydrogen-bond-promoted C-N bond cleavage of the allyl amines and a Ru(II)/Ru(IV) catalytic cycle.

Experimental

All reactions were performed under nitrogen atmosphere using standard Schlenk and vacuum line techniques. Toluene and THF were purified by JC Meyer Phoenix Solvent Systems. DCE was dried over CaH₂ and distilled under nitrogen. DMSO and DMF were dried over 4 Å molecular sieve, fractionally distilled under reduced pressure and stored under nitrogen. CF₃CH₂OH was dried over 4 Å molecular sieve and distilled under nitrogen. MeOH and EtOH were treated with Mg and then distilled under nitrogen. [Ru(p-cymene)Cl₂]₂ was purchased from TCI (Shanghai) Development Co., Ltd. 2-Arylpyridines¹³ and allylic amines^{9c,14} were synthesized according to the reported methods. All other chemicals were obtained from commercial vendors and used as received. NMR spectra were recorded on a Bruker Avance III 400 spectrometer at ambient temperature. The chemical shifts of the ¹H NMR spectra were referenced to TMS or internal solvent resonances and the chemical shifts of the ¹³C NMR spectra were referenced to internal solvent resonances. The chemical shifts of the ¹⁹F NMR spectra were referenced to external CF₃COOH. High-resolution mass spectra (HR-MS) were acquired in the ESI mode using an Orbitrap mass analyzer.

Synthesis of 2-(3-fluorophenyl)pyridine and 2-(3-chlorophenyl)pyridine

2-(3-Fluorophenyl)pyridine and 2-(3-chlorophenyl)pyridine were synthesized according to the reported method.^{13a}

2-(3-Fluorophenyl)pyridine. ¹H NMR (400 MHz, CDCl₃): δ 8.68 (d, *J* = 4.7 Hz, 1H), 7.81–7.64 (m, 4H), 7.47–7.36 (m, 1H), 7.28–7.19 (m, 1H), 7.09 (dt, *J* = 8.4, 2.2 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃): δ 163.38 (d, *J* = 246.3 Hz), 156.08 (d, *J* = 2.7 Hz), 149.82 , 141.77 (d, *J* = 7.6 Hz), 136.95 , 130.29 (d, *J* = 8.2 Hz), 122.73, 122.47 (d, *J* = 2.8 Hz), 120.63 , 115.85 (d, *J* = 21.3 Hz), 113.93 (d, *J* = 22.8 Hz). ¹⁹F NMR (376 MHz, CDCl₃): δ –112.91. HR-MS: m/z 174.0705 [M+H]⁺, calcd for C₁₁H₉NF 174.0714.

2-(3-Chlorophenyl)pyridine. ¹H NMR (400 MHz, CDCl₃): δ 8.69 (d, *J* = 4.7 Hz, 1H), 8.01 (s, 1H), 7.89–7.82 (m, 1H), 7.75 (dt, *J* = 7.7, 1.6 Hz, 1H), 7.69 (d, *J* = 7.9 Hz, 1H), 7.43–7.35 (m, 2H), 7.28–7.21 (m, 1H). ¹³C NMR (101 MHz, CDCl₃): δ 156.03, 149.88, 141.25, 137.01, 134.95, 130.07, 129.03, 127.20, 125.04, 122.77, 120.68. HR-MS: m/z 190.0408 [M+H]⁺, calcd for C₁₁H₉NCl 190.0418.

General procedure for the allylation of arenes with allylic amines

2-Arylpyridines (0.2 mmol), allylic amines (2 or 4 equiv.), AgOAc (0.5 equiv.), $[Ru(p-cymene)Cl_2]_2$ (5 mol %), and CF₃CH₂OH (1.5 cm³) were successively added into a Schlenk tube. The mixture was stirred at 75 °C for 12 hours. Upon cooling to room temperature, the resulting mixture was diluted with EtOAc and filtered through a short pad of silica gel. The filtrate was concentrated under reduced pressure and the residue was purified by column chromatography to afford the desired product.

2-(2,6-Diallylphenyl)pyridine (3aa). Elution with EtOAc/ petroleum ether 1/20 (v/v), colorless oil, yield 42.4 mg (90%). ¹H NMR (400 MHz, CDCl₃): δ 8.70 (d, *J* = 4.1 Hz, 1H), 7.70 (t, *J* =

ARTICLE

7.6 Hz, 1H), 7.33–7.21 (m, 3H), 7.16 (d, J = 7.6 Hz, 2H), 5.88-5.70 (m, 2H), 4.91 (d, J = 10.0 Hz, 2H), 4.80 (d, J = 17.0 Hz, 2H), 3.23–3.00 (m, 4H). ¹³C NMR (101 MHz, CDCl₃): δ 159.03, 149.49, 140.09, 138.06, 137.36, 135.91, 128.35, 127.40, 125.24, 121.96, 115.57, 37.98. HR-MS: m/z 236.1422 [M+H]⁺, calcd for C₁₇H₁₈N 236.1434.

2-(2-Allyl-6-methylphenyl)pyridine (3ba). Elution with EtOAc/ petroleum ether 1/20 (v/v), colorless oil, yield 36.9 mg (88%). ¹H NMR (400 MHz, CDCl₃): δ 8.71 (d, *J* = 4.7 Hz, 1H), 7.73 (dt, *J* = 7.7, 1.8 Hz, 1H), 7.30–7.20(m, 3H), 7.13 (d, *J* = 7.6 Hz, 2H), 5.87-5.72 (m, 1H), 4.94–4.87 (m, 1H), 4.84–4.76 (m, 1H), 3.12 (s, 2H), 2.04 (s, 3H). ¹³C NMR (101 MHz, CDCl₃): δ 159.52, 149.64, 140.31, 137.80, 137.43, 136.18, 136.12, 128.15, 128.08, 126.93, 124.88, 121.86, 115.50, 37.95, 20.40. HR-MS: m/z 210.1279 [M+H]⁺, calcd for C₁₅H₁₆N 210.1277.

2-(2-Allyl-6-fluorophenyl)pyridine (3ca). Elution with EtOAc/petroleum ether 1/20 (v/v), colorless oil, yield 24.2mg (57%). ¹H NMR (400 MHz, CDCl₃): δ 8.72 (d, J = 4.7 Hz, 1H), 7.74 (t, J = 7.7 Hz, 1H), 7.36 (d, J = 7.7 Hz, 1H), 7.34-7.23 (m, 2H), 7.10 (d, J = 7.7 Hz, 1H), 7.02 (t, J = 8.9 Hz, 1H), 5.86-5.70 (m, 1H), 4.92 (d, J = 10.1 Hz, 1H), 4.83 (d, J = 17.0 Hz, 1H), 3.33 (d, J = 6.6 Hz, 2H). ¹³C NMR (101 MHz, CDCl₃): δ 160.21 (d, J =246.5 Hz), 154.01, 149.56, 140.98 (d, J = 2.4 Hz), 136.73, 136.15, 129.61 (d, J = 9.0 Hz), 128.30 (d, J = 15.5 Hz), 125.86 (d, J = 1.7 Hz), 125.33 (d, J = 3.1 Hz), 122.48 , 115.98 , 113.53 (d, J = 22.7 Hz), 37.25 (d, J = 2.6 Hz).¹⁹F NMR (376 MHz, CDCl₃): δ – 116.53. HR-MS: m/z 214.1030 [M+H]⁺, calcd for C₁₄H₁₃FN 214.1027.

2-(2-Allyl-4,6-difluorophenyl)pyridine (3da). Elution with EtOAc/petroleum ether 1/20 (v/v), colorless oil, yield 21.1 mg (47%). ¹H NMR (400 MHz, CDCl₃): δ 8.72 (d, *J* = 4.4 Hz, 1H), 7.75 (t, *J* = 7.7 Hz, 1H), 7.34 (d, *J* = 7.8 Hz, 1H), 7.31–7.25 (m, 1H), 6.86 (d, *J* = 9.4 Hz, 1H), 6.77 (t, *J* = 9.1 Hz, 1H), 5.83–5.69 (m, 1H), 4.98 (d, *J* = 10.0 Hz, 1H), 4.87 (d, *J* = 17.0 Hz, 1H), 3.31 (d, *J* = 6.6 Hz, 2H). ¹³C NMR (101 MHz, CDCl₃): δ 162.51 (dd, *J* = 249.6, 13.2 Hz), 160.43 (dd, *J* = 248.8, 12.7 Hz), 153.24, 149.69 , 142.82 (dd, *J* = 8.9, 3.6 Hz), 136.31, 135.83 , 125.99 (d, *J* = 1.6 Hz), 124.55 (dd, *J* = 15.7, 3.8 Hz), 122.65 , 116.81 , 112.32 (dd, *J* = 21.4, 3.4 Hz), 101.91 (dd, *J* = 26.9, 25.6 Hz), 37.26 (dd, *J* = 2.6, 1.8 Hz). ¹⁹F NMR (376 MHz, CDCl₃): δ -110.27 (d, *J* = 7.6 Hz), -112.38 (d, *J* = 7.6 Hz). HR-MS: m/z 232.0933 [M+H]⁺, calcd for C₁₄H₁₂F₂N 232.0932.

2-(2-Allyl-6-chlorophenyl)pyridine (3ea). Elution with EtOAc/ petroleum ether 1/20 (v/v), colorless oil, yield 37.2 mg (81%). ¹H NMR (400 MHz, CDCl₃): δ 8.71 (d, *J* = 4.4 Hz, 1H), 7.74 (t, *J* = 7.6 Hz, 1H), 7.34 (d, *J* = 7.9 Hz, 1H), 7.31–7.23 (m, 3H), 7.20 (d, *J* = 7.6 Hz, 1H), 5.86-5.67 (m, 1H), 4.93 (d, *J* = 10.0 Hz, 1H), 4.81 (d, *J* = 17.0 Hz, 1H), 3.17 (d, *J* = 6.5 Hz, 2H). ¹³C NMR (101 MHz, CDCl₃): δ 157.08, 149.48, 140.49, 139.07, 136.44, 136.11, 133.27, 129.25, 127.96, 127.39, 125.37, 122.45, 116.11, 37.93. HR-MS: m/z 230.0728 [M+H]⁺, calcd for C₁₄H₁₃ClN 230.0731.

2-(2-Allyl-6-bromophenyl)pyridine (3fa). Elution with EtOAc/ petroleum ether 1/20 (v/v), colorless oil, yield 36.4 mg (66%). ¹H NMR (400 MHz, CDCl₃): δ 8.76–8.67 (m, 1H), 7.75 (dt, *J* = 7.7, 1.8 Hz, 1H), 7.52 (dd, *J* = 7.8, 1.0 Hz, 1H), 7.33–7.23 (m, 3H), 7.20 (t, *J* = 7.7 Hz, 1H), 5.84–5.69 (m, 1H), 4.97-4.89 (m, 1H), 4.86–4.76 (m, 1H), 3.23-3.07 (m, 2H). ¹³C NMR (101 MHz,

CDCl₃): δ 158.63, 149.45, 140.93, 140.56, 136.47, 136.17, 130.60, 129.62, 128.57, 125.26, 123.36, 122.53, 116.19, 38.27. HR-MS: m/z 274.0213 [M+H]⁺, calcd for C₁₄H₁₃BrN 274.0226.

2-(2-Allyl-6-(trifluoromethyl)phenyl)pyridine (3ga). Elution with EtOAc/petroleum ether 1/20 (v/v), colorless oil, yield 35.6 mg (68%). ¹H NMR (400 MHz, CDCl₃): δ 8.69 (d, *J* = 4.2 Hz, 1H), 7.73 (dt, *J* = 7.7, 1.8 Hz, 1H), 7.63 (d, *J* = 7.6 Hz, 1H), 7.55–7.40 (m, 2H), 7.35–7.23 (m, 2H), 5.85–5.68 (m, 1H), 5.01-4.90 (m, 1H), 4.88–4.77 (m, 1H), 3.20-2.99 (m, 2H). ¹³C NMR (101 MHz, CDCl₃): δ 156.51, 149.11, 140.30, 138.76, 136.34, 135.83, 133.06, 128.95 (q, *J* = 29.9 Hz), 128.37, 125.12, 125.11, 124.14 (q, *J* = 275.2 Hz), 124.03 (q, *J* = 5.3 Hz), 122.58, 116.41, 37.44. ¹⁹F NMR (376 MHz, CDCl₃): δ –57.29. HR-MS: m/z 264.0993 [M+H]⁺, calcd for C₁₅H₁₃F₃N 264.0995.

2-(2-Allyl-5-methylphenyl)pyridine (3ha). Elution with EtOAc/petroleum ether 1/20 (v/v), colorless oil, yield 23.0 mg (55%). ¹H NMR (400 MHz, CDCl₃): δ 8.68 (d, J = 4.4 Hz, 1H), 7.71 (t, J = 7.7 Hz, 1H), 7.39 (d, J = 7.8 Hz, 1H), 7.27-7.12 (m, 4H), 5.94-5.79 (m, 1H), 4.94 (d, J = 10.0 Hz, 1H), 4.88 (d, J = 17.1 Hz, 1H), 3.44 (d, J = 6.3 Hz, 2H), 2.36 (s, 3H). ¹³C NMR (101 MHz, CDCl₃): δ 159.98, 149.27, 140.33, 137.95, 136.12, 135.91, 134.57, 130.60, 130.11, 129.27, 124.24, 121.76, 115.50, 37.10, 21.07. HR-MS: m/z 210.1274 [M+H]⁺, calcd for C₁₅H₁₆N 210.1277.

2-(2-Allyl-4,5-dimethylphenyl)pyridine (3ia). Elution with EtOAc/petroleum ether 1/20 (v/v), colorless oil, yield 17.9 mg (40%). ¹H NMR (400 MHz, CDCl₃): δ 8.67 (d, *J* = 4.2 Hz, 1H), 7.69 (dt, *J* = 7.7, 1.8 Hz, 1H), 7.38 (d, *J* = 7.8 Hz, 1H), 7.24–7.16 (m, 2H), 7.07 (s, 1H), 5.94–5.81 (m, 1H), 4.99–4.85 (m, 2H), 3.43 (d, *J* = 6.4 Hz, 2H), 2.29 (s, 3H), 2.27 (s, 3H). ¹³C NMR (101 MHz, CDCl₃): δ 159.98, 149.27, 138.15, 138.02, 136.93, 136.05, 134.87, 134.57, 131.45, 131.20, 124.25, 121.55, 115.38, 37.10, 19.63, 19.36. HR-MS: m/z 224.1423 [M+H]⁺, calcd for C₁₆H₁₈N 224.1434.

2-(4-Allyl-[1,1'-biphenyl]-3-yl)pyridine (3ja). Elution with EtOAc/petroleum ether 1/20 (v/v), colorless oil, yield 27.1 mg (50%). ¹H NMR (400 MHz, CDCl₃): δ 8.70 (d, *J* = 4.8 Hz, 1H), 7.73 (dt, *J* = 7.7, 1.8 Hz, 1H), 7.66–7.55 (m, 4H), 7.48–7.36 (m, 4H), 7.32 (t, *J* = 7.3 Hz, 1H), 7.28–7.22 (m, 1H), δ 5.97–5.84 (m, 1H), 5.02–4.88 (m, 2H), 3.52 (d, *J* = 6.5 Hz, 2H). ¹³C NMR (101 MHz, CDCl₃): δ 159.87, 149.30, 140.89, 140.81, 139.33, 137.57, 136.90, 136.31, 130.65, 128.82, 128.75, 127.30, 124.28, 121.95, 115.82, 37.24. HR-MS: m/z 272.1421 [M+H]⁺, calcd for C₂₀H₁₈N 272.1434.

2-(3-Allylnaphthalen-2-yl)pyridine (3ka). Elution with EtOAc/petroleum ether 1/20 (v/v), colorless oil, yield 25.0 mg (51%). ¹H NMR (400 MHz, CDCl₃): δ 8.76–8.67 (m, 1H), 7.90-7.80 (m, 3H), 7.79–7.72 (m, 2H), 7.53–7.40 (m, 3H), 7.31-7.25 (m, 1H), 5.97-5.83 (m, 1H), 5.01–4.94 (m, 1H), 4.93–4.85 (m, 1H), 3.68 (d, *J* = 6.5 Hz, 2H). ¹³C NMR (101 MHz, CDCl₃): δ 160.04, 149.18, 139.25, 137.46, 136.40, 135.98, 133.49, 132.12, 129.32, 128.54, 127.97, 127.36, 126.46, 125.83, 124.50, 121.95, 115.95, 37.86. HR-MS: m/z 246.1264 [M+H]⁺, calcd for C₁₈H₁₆N 246.1277.

2-(2-AllyInaphthalen-1-yI)pyridine (3Ia). Elution with EtOAc/ petroleum ether 1/20 (v/v), colorless oil, yield 41.7 mg (85%). ¹H NMR (400 MHz, CDCl₃): δ 8.79 (d, J = 4.7 Hz, 1H), 7.89-7.81

Journal Name

(m, 2H), 7.78 (t, J = 7.6 Hz, 1H), 7.46–7.26 (m, 6H), 5.95–5.81 (m, 1H), 4.96 (d, J = 10.1 Hz, 1H), 4.89 (d, J = 17.1 Hz, 1H), 3.38–3.22 (m, 2H). ¹³C NMR (101 MHz, CDCl₃): δ 158.58, 149.81, 137.36, 136.88, 136.15, 135.27, 132.60, 132.34, 128.50, 127.95, 127.82, 126.24, 125.91, 125.78, 125.27, 122.20, 115.78, 38.09. HR-MS: m/z 246.1276 [M+H]⁺, calcd for C₁₈H₁₆N 246.1277.

2-(2,6-Diallyl-4-methylphenyl)pyridine (3ma). Elution with EtOAc/petroleum ether 1/20 (v/v), colorless oil, yield 42.7 mg (86%). ¹H NMR (400 MHz, CDCl₃): δ 8.69 (d, *J* = 4.2 Hz, 1H), 7.69 (t, *J* = 7.6 Hz, 1H), 7.27-9.19 (m, 2H), 6.97 (s, 2H), 5.88–5.68 (m, 2H), 4.90 (d, *J* = 10.0 Hz, 2H), 4.81 (d, *J* = 17.0 Hz, 2H), 3.17–3.00 (m, 4H), 2.35 (s, 3H). ¹³C NMR (101 MHz, CDCl₃): δ 159.20, 149.48, 137.93, 137.92, 137.53, 137.37, 135.86, 128.10, 125.47, 121.83, 115.47, 38.00, 21.35. HR-MS: m/z 250.1592 [M+H]⁺, calcd for C₁₈H₂₀N 250.1590.

2-(3,5-Diallyl-[1,1'-biphenyl]-4-yl)pyridine (3na). Elution with EtOAc/petroleum ether 1/20 (v/v), colorless oil, yield 46.3 mg (74%). ¹H NMR (400 MHz, CDCl₃): δ 8.72 (d, *J* = 4.8 Hz, 1H), 7.73 (dt, *J* = 7.7, 1.8 Hz, 1H), 7.66–7.59 (m, 2H), 7.44 (t, *J* = 7.6 Hz, 2H), 7.40 (s, 2H), 7.34 (t, *J* = 7.3 Hz, 2H), 7.31–7.24 (m, 2H), 5.90–5.77 (m, 2H), 4.99–4.90 (m, 2H), 4.89–4.81 (m, 2H), 3.29–3.08 (m, 4H). ¹³C NMR (101 MHz, CDCl₃): δ 158.88, 149.60, 141.21, 139.16, 138.61, 137.27, 135.99, 128.80, 127.38, 127.32, 126.32, 125.36, 122.05, 115.84, 38.16. HR-MS: m/z 312.1749 [M+H]⁺, calcd for C₂₃H₂₂N 312.1747.

2-(2,6-Diallyl-4-methoxyphenyl)pyridine (30a). Elution with EtOAc/petroleum ether 1/20 (v/v), colorless oil, yield 44 mg (83%). ¹H NMR (400 MHz, CDCl₃): δ 8.61 (d, *J* = 4.4 Hz, 1H), 7.61 (t, *J* = 7.6 Hz, 1H), 7.20–7.10 (m, 2H), 6.83 (s, 2H), 5.78–5.62 (m, 2H), 4.84 (d, *J* = 10.0 Hz, 2H), 4.74 (d, *J* = 17.0 Hz, 2H), 3.73 (s, 3H), 3.11–2.92 (m, 4H). ¹³C NMR (101 MHz, CDCl₃): δ 159.30, 158.95, 149.46, 139.65, 137.12, 135.88, 133.02, 125.73, 121.80, 115.77, 112.68, 55.26, 38.16. HR-MS: m/z 266.1541 [M+H]⁺, calcd for C₁₈H₂₀NO 266.1539.

3,5-Diallyl-4-(pyridin-2-yl)phenol (3pa). Elution with EtOAc/ petroleum ether 1/3 (v/v), white solid, yield 36.3 mg (72%). ¹H NMR (400 MHz, CDCl₃): δ 9.96-9.23 (b, 1H), 8.67 (d, *J* = 3.8 Hz, 1H), 7.75 (t, *J* = 7.3 Hz, 1H), 7.36–7.22 (m, 2H), 6.39 (s, 2H), 5.75–5.60 (m, 2H), 4.83 (d, *J* = 9.8 Hz, 2H), 4.71 (d, *J* = 17.0 Hz, 2H), 3.08–2.84 (m, 4H). ¹³C NMR (101 MHz, CDCl₃): δ 158.94, 156.93, 148.44, 139.27, 137.15, 136.77, 130.95, 126.59, 122.28, 115.55, 115.465, 38.01. HR-MS: m/z 252.1377 [M+H]⁺, calcd for C₁₇H₁₈NO 252.1383.

2-(2,6-Diallyl-4-fluorophenyl)pyridine (3qa). Elution with EtOAc/petroleum ether 1/20 (v/v), colorless oil, yield 33.1 mg (65%). ¹H NMR (400 MHz, CDCl₃): δ 8.71 (d, *J* = 4.4 Hz, 1H), 7.73 (dt, *J* = 7.7, 1.8 Hz, 1H), 7.31–7.25 (m, 1H), 7.22 (d, *J* = 8.0 Hz, 1H), 6.88 (d, *J* = 9.6 Hz, 2H), 5.85–5.69 (m, 2H), 4.96 (dd, *J* = 10.4, 1.6 Hz, 2H), 4.84 (dd, *J* = 17.2, 1.6 Hz, 2H), 3.20–2.97 (m, 4H). ¹³C NMR (101 MHz, CDCl₃) δ 162.57 (d, *J* = 246.7 Hz), 158.30, 149.70, 140.74 (d, *J* = 7.7 Hz), 136.49, 136.15, 136.12, 125.49, 122.20, 116.38, 113.98 (d, *J* = 21.4 Hz), 37.92 (d, *J* = 1.6 Hz). ¹⁹F NMR (376 MHz, CDCl₃): δ –114.36. HR-MS: m/z 254.1341 [M+H]⁺, calcd for C₁₇H₁₇FN 254.1340.

2-(2,6-Diallyl-4-chlorophenyl)pyridine (3ra). Elution with EtOAc/petroleum ether 1/20 (v/v), colorless oil, yield 38.3 mg

(71%). ¹H NMR (400 MHz, CDCl₃): δ 8.71 (d, *J* = 4.6 Hz, 1H), 7.72 (t, *J* = 7.9 Hz, 1H), 7.32–7.24 (m, 1H), 7.21 (d, *J* = 7.8 Hz, 1H), 7.16 (s, 2H), 5.87–5.66 (m, 2H), 4.96 (d, *J* = 10.1 Hz, 2H), 4.83 (d, *J* = 17.4 Hz, 2H), 3.18–2.96 (m, 4H). ¹³C NMR (101 MHz, CDCl₃): δ 158.02, 149.71, 140.17, 138.57, 136.42, 136.15, 133.95, 127.32, 125.28, 122.29, 116.43, 37.77. HR-MS: m/z 270.1047 [M+H]⁺, calcd for C₁₇H₁₇CIN 270.1044.

2-(2,6-Diallyl-4-bromophenyl)pyridine (3sa). Elution with EtOAc/petroleum ether 1/20 (v/v), colorless oil, yield 40.8 mg (65%). ¹H NMR (400 MHz, CDCl₃): δ 8.70 (d, *J* = 4.8 Hz, 1H), 7.73 (dt, *J* = 7.7, 1.7 Hz, 1H), 7.31 (s, 2H), 7.30–7.24 (m, 1H), 7.21 (d, *J* = 7.7 Hz, 1H), 5.83-5.67 (m, 2H), 5.00–4.91 (m, 2H), 4.88–4.78 (m, 2H), 3.16–2.98 (m, 4H). ¹³C NMR (101 MHz, CDCl₃): δ 158.02, 149.71, 140.44, 139.06, 136.41, 136.15, 130.25, 125.22, 122.31, 116.46, 37.72. HR-MS: m/z 314.0541 [M+H]⁺, calcd for C₁₇H₁₇BrN 314.0539.

Ethyl 3,5-diallyl-4-(pyridin-2-yl)benzoate (3ta). Elution with EtOAc/petroleum ether 1/20 (v/v), white solid, yield 49.5 mg (81%). ¹H NMR (400 MHz, CDCl₃): δ 8.77–8.67 (m, 1H), 7.85 (s, 2H), 7.75 (dt, *J* = 7.7, 1.8 Hz, 1H), 7.34–7.27 (m, 1H), 7.23 (d, *J* = 7.7 Hz, 1H), 5.86-5.72 (m, 2H), 5.02-4.88 (m, 2H), 4.86–4.76 (m, 2H), 4.39 (q, *J* = 7.1 Hz, 2H), 3.26–3.05 (m, 4H), 1.41 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃): δ 166.66, 158.11, 149.59, 144.39, 138.61, 136.65, 136.10, 130.30, 128.61, 124.94, 122.37, 116.15, 61.08, 37.87, 14.44. HR-MS: m/z 308.1639 [M+H]⁺, calcd for C₂₀H₂₂NO₂ 308.1645.

3,5-Diallyl-4-(pyridin-2-yl)benzoic acid (3ua). Elution with EtOAc/petroleum ether 1/3 (v/v), white solid, yield 39.6 mg (71%). ¹H NMR (400 MHz, DMSO-*d*₆): δ 13.04 (b, 1H), 8.69 (d, *J* = 4.3 Hz, 1H), 7.88 (dt, *J* = 7.7, 1.7 Hz, 1H), 7.75 (s, 2H), 7.45–7.38 (m, 1H), 7.33 (d, *J* = 7.7 Hz, 1H), 5.80–5.66 (m, 2H), 4.96-4.88 (m, 2H), 4.87–4.78 (m, 2H), 3.09 (s, 4H). ¹³C NMR (101 MHz, DMSO-*d*₆): δ 167.18, 157.24, 149.41, 144.22, 138.25, 136.66, 136.40, 130.37, 128.04, 124.74, 122.65, 116.20, 37.21. HR-MS: m/z 280.1328 [M+H]⁺, calcd for C₁₈H₁₈NO₂ 280.1332.

2-(2,6-DiallyI-4-(trifluoromethyl)phenyl)pyridine (3va). Elution with EtOAc/petroleum ether 1/20 (v/v), colorless oil, yield 41.8 mg (69%). ¹H NMR (400 MHz, CDCl₃): δ 8.72 (d, *J* = 4.8 Hz, 1H), 7.76 (dt, *J* = 7.7, 1.7 Hz, 1H), 7.43 (s, 2H), 7.34–7.28 (m, 1H), 7.23 (d, *J* = 7.7 Hz, 1H), 5.85–5.70 (m, 2H), 4.98 (dd, *J* = 10.0, 1.1 Hz, 2H), 4.84 (dd, *J* = 17.0, 1.5 Hz, 2H), 3.25–3.05 (m, 4H). ¹³C NMR (101 MHz, CDCl₃): δ 157.77, 149.81, 143.47, 139.31, 136.24, 130.50 (q, *J* = 32.1 Hz), 124.92, 124.29 (q, *J* = 273.4 Hz), 124.18 (q, *J* = 3.7 Hz), 122.52, 116.63, 37.88. ¹⁹F NMR (376 MHz, CDCl₃): δ –62.55. HR-MS: m/z 304.1289 [M+H]⁺, calcd for C₁₈H₁₇F₃N 304.1308.

2-(2,6-Diallyl-4-nitrophenyl)pyridine (**3wa**). Elution with EtOAc/petroleum ether 1/10 (v/v), colorless oil, yield 25.1 mg (45%). ¹H NMR (400 MHz, CDCl₃): δ 8.79–8.71 (m, 1H), 8.05 (s, 2H), 7.81 (dt, *J* = 7.7, 1.7 Hz, 1H), 7.43–7.33 (m, 1H), 7.26 (d, *J* = 7.8 Hz, 1H), 5.88-5.72 (m, 2H), 5.10–4.98 (m, 2H), 4.97–4.79 (m, 2H), 3.29–3.08 (m, 4H). ¹³C NMR (101 MHz, CDCl₃): δ 156.90, 149.90, 147.77, 146.18, 140.49, 136.45, 135.52, 124.65, 122.86, 122.21, 117.24, 37.77. HR-MS: m/z 281.1285 [M+H]⁺, calcd for C₁₇H₁₇N₂O₂ 281.1285.

 $2\-(2,6\-Diallyl-3\-methoxyphenyl)pyridine (3xa).$ Elution with EtOAc/petroleum ether 1/20 (v/v), colorless oil, yield 42.3 mg

DOI: 10.1039/C8OB00723C

Journal Name

ARTICLE

(80%). ¹H NMR (400 MHz, CDCl₃): δ 8.72-8.66 (m, 1H), 7.69 (dt, J = 7.7, 1.8 Hz, 1H), 7.29–7.18 (m, 2H), 7.12 (d, J = 8.4 Hz, 1H), 6.89 (d, J = 8.5 Hz, 1H), 5.86–5.70 (m, 2H), 4.92–4.85 (m, 1H), 4.84–4.74 (m, 2H), 4.69–4.60 (m, 1H), 3.83 (s, 3H), 3.28–3.18 (m, 1H), 3.11–2.94 (m, 3H). ¹³C NMR (101 MHz, CDCl₃): δ 158.93, 156.10, 149.33, 141.41, 137.80, 136.95, 135.72, 130.15, 128.01, 126.55, 125.28, 121.97, 115.18, 114.40, 110.62, 55.83, 37.43, 31.81. HR-MS: m/z 266.1534 [M+H]⁺, calcd for C₁₈H₂₀NO 266.1539.

2-(2,6-Diallyl-3-fluorophenyl)pyridine (**3ya**). Elution with EtOAc/petroleum ether 1/20 (v/v), colorless oil, yield 41.5 mg (82%). ¹H NMR (400 MHz, CDCl₃): δ 8.70 (d, *J* = 4.4 Hz, 1H), 7.72 (t, *J* = 7.6 Hz, 1H), 7.32–7.25 (m, 1H), 7.23 (d, *J* = 7.8 Hz, 1H), 7.16–7.09 (m, 1H), 7.04 (t, *J* = 8.9 Hz, 1H), 5.85–5.67 (m, 2H), 4.91 (d, *J* = 10.3 Hz, 1H), 4.87 (d, *J* = 10.1 Hz, 1H), 4.79 (d, *J* = 17.0 Hz, 1H), 4.72 (d, *J* = 17.1 Hz, 1H), 3.31–3.16 (m, 1H), 3.15-2.96 (m, 3H). ¹³C NMR (101 MHz, CDCl₃): δ 159.87 (d, *J* = 244.2 Hz), 157.80 (d, *J* = 2.8 Hz), 149.48, 141.90 (d, *J* = 4.2 Hz), 137.12, 135.93, 135.80, 133.78 (d, *J* = 3.5 Hz), 128.66 (d, *J* = 8.6 Hz), 125.17 (d, *J*=16.2), 125.14, 122.30, 115.70, 115.24, 115.00 (d, *J* = 22.5 Hz), 37.40, 30.88 (d, *J* = 3.1 Hz). ¹⁹F NMR (376 MHz, CDCl₃): δ -120.17. HR-MS: m/z 254.1332 [M+H]⁺, calcd for C₁₇H₁₇FN 254.1340.

2-(2,6-Diallyl-3-chlorophenyl)pyridine (**3***z***a**). Elution with EtOAc/petroleum ether 1/20 (v/v), colorless oil, yield 31.3 mg (58%). ¹H NMR (400 MHz, CDCl₃): δ 8.70 (d, *J* = 4.8 Hz, 1H), 7.72 (dt, *J* = 7.7, 1.8 Hz, 1H), 7.37 (d, *J* = 8.3 Hz, 1H), 7.31–7.25 (m, 1H), 7.22 (d, *J* = 7.8 Hz, 1H), 7.11 (d, *J* = 8.3 Hz, 1H), 5.84–5.68 (m, 2H), 4.96–4.87 (m, 2H), 4.84-4.76 (m, 1H), 4.73–4.63 (m, 1H), 3.39–3.29 (m, 1H), 3.19–3.11 (m, 1H), 3.11–2.94 (m, 2H). ¹³C NMR (101 MHz, CDCl₃): δ 158.29, 149.53, 142.15, 137.08, 136.75, 135.98, 135.44, 135.11, 132.83, 129.41, 128.62, 125.14, 122.37, 116.03, 115.67, 37.66, 35.32. HR-MS: m/z 270.1031 [M+H]⁺, calcd for C₁₇H₁₇ClN 270.1044.

1-(2,6-Diallylphenyl)-1*H***-pyrazole (4).** Elution with EtOAc/ petroleum ether 1/20 (v/v), colorless oil, yield 31.0 mg (69%). ¹H NMR (400 MHz, CDCl₃): δ 7.72 (d, *J* = 1.5 Hz, 1H), 7.44 (d, *J* = 2.2 Hz, 1H), 7.35 (t, *J* = 7.6 Hz, 1H), 7.19 (d, *J* = 7.7 Hz, 2H), 6.42 (t, *J* = 2.0 Hz, 1H), 5.89–5.72 (m, 2H), 5.03–4.94 (m, 2H), 4.93–4.85 (m, 2H), 3.02 (d, *J* = 14.4 Hz, 4H). ¹³C NMR (101 MHz, CDCl₃): δ 140.20, 138.57, 138.45, 136.76, 131.91, 129.45, 128.06, 116.24, 105.79, 35.53. HR-MS: m/z 225.1376 [M+H]⁺, calcd for C₁₇H₁₇ClN 225.1386.

2-(2,6-Diallylphenyl)pyrimidine (5). Elution with EtOAc/ petroleum ether 1/20 (v/v), colorless oil, yield 36.8 mg (78%). ¹H NMR (400 MHz, CDCl₃): δ 8.84 (d, *J* = 4.9 Hz, 2H), 7.34–7.28 (m, 1H), 7.26 (t, *J* = 5.0 Hz, 1H), 7.17 (d, *J* = 7.6 Hz, 2H), 5.83– 5.71 (m, 2H), 4.85 (dq, *J* = 10.0, 2.0 Hz, 2H), 4.77 (dq, *J* = 16.8, 2.0 Hz, 2H), 3.21 (d, *J* = 6.8 Hz, 4H). ¹³C NMR (101 MHz, CDCl₃): δ 167.92, 156.93, 138.65, 137.93, 137.00, 128.94, 127.63, 119.11, 115.51, 38.04. HR-MS: m/z 237.1389 [M+H]⁺, calcd for C₁₆H₁₇N₂ 237.1386.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

Financial support from the National Natural Science Foundation of China (Grant No. 21372212) and the National Basic Research Program of China (Grant No. 2015CB856600) is greatly acknowledged.

Notes and references

- (a) S. R. Chemler, and P. H. Fuller, *Chem. Soc. Rev.*, 2007, **36**, 1153;
 (b) J. A. Marshal, *Chem. Rev.*, 2000, **100**, 3163;
 (c) G. Ni, Q. Zhang, Z. Zheng, R. Chen, and D. Yu, *J. Nat. Prod.*, 2009, **72**, 966.
- 2 (a) B. M. Trost, T. Zhang, and J. D. Sieber, *Chem. Sci.*, 2010, 1, 427; (b) Q. Lu, F. J. R. Klauck, and F. Glorius, *Chem. Sci.*, 2017, 8, 3379; (c) H. Wang, M. M. Lorion, and L. Ackermann, *ACS Catal.*, 2017, 7, 3430; (d) L. Dong, and Y. Q. Xia, *Org. Lett.*, 2017, 19, 2258; (e) Y. Taklhama, Y. Shibata, and K. Tanaka, *Org. Lett.*, 2016, 18, 2934; (f) Z. Qi, L. Z. Kong, and X. W. Li, *Org. Lett.*, 2015, 18, 4392; (g) N. A. Butta, and W. Zhang, *Chem. Soc. Rev.*, 2015, 44, 7929.
- 3 (a) H. Dai, C. Yu, C. Lu, and H. Yan, *Eur. J. Org. Chem.*, 2016, 1255; (b) N. Barsu, D. Kalsi, and B. Sundararaju, *Chem. -Eur. J.*, 2015, **21**, 9364; (c) Y. Goriya, and C. V. Ramana, *Chem. -Eur. J.*, 2012, **18**, 13288.
- 4 (a) G. S. Kumar, and M. Kapur, Org. Lett., 2016, 18, 1112; (b)
 Y. Suzuki, B. Sun, K. Sakata, T. Yoshino, S. Matsunaga, and M. Kanai, Angew. Chem. Int. Ed. 2015, 54, 9944; (c) Y. Bunno, N. Murakami, Y. Suzuki, M. Kanai, T. Yoshino, and S. Matsunaga, Org. Lett., 2016, 18, 2216; (d) G. Onodera, H. Imajima, M. Yamanashi, Y. Nishibayashi, M. Hidai, and S. Uemura, Organometallics, 2004, 23, 5841.
- 5 (a) M. Kim, S. Sharma, N. K. Mishra, S. Han, J. Park, M. Kim, Y. Shin, J. H. Kwak, S. H. Han, and I. S. Kim, *Chem. Commun.*, 2014, **50**, 11303; (b) R. Manikandan, and M. Jeganmohan, *Org. Biomol. Chem.*, 2016, **14**, 7691; (c) H. Wang, N. Schroder, and F. Glorius, *Angew. Chem. Int. Ed.*, 2013, **52**, 5386; (d) A. Cajaraville, S. Lopez, J. A. Varela, and C. Saá, *Org. Lett.*, 2013, **15**, 4576; (e) W. Liu, S. C. Richter, Y. Zhang, and L. Ackermann, *Angew. Chem. Int. Ed.*, 2016, **55**, 7747; (f) R. Manikandan, P. Madasamy, and M. Jeganmohan, *Chem. -Eur. J.*, 2015, **21**, 13934. (g) S. Oi, Y. Tanaka, and Y. Inoue, *Organometallics*, 2006, **25**, 4773.
- 6 (a) Y. J. Zhang, E. Skucas, and M. J. Krische, Org. Lett., 2009, 11, 4248; (b) Z. Fang, C. Fu, and S. Ma, Chem. -Eur. J., 2010, 16, 3910; (c) R. Zeng, C. Fu, and S. Ma, J. Am. Chem. Soc., 2012, 134, 9597; (d) B. Ye, and N. Cramer, J. Am. Chem. Soc., 2013, 135, 636; (e) S. Nakanowatari, and L. Ackermann, Chem. -Eur. J., 2015, 21, 16246.
- 7 S. E. Korkis, D. J. Burns, and H. W. Lam, J. Am. Chem. Soc., 2016, **138**, 12252.
- 8 (a) Y. Gu, and S.-K. Tian, Synlett, 2013, 24, 1170; (b) K. B. Ouyang, W. Hao, W. X. Zhang, and Z. F. Xi, Chem. Rev., 2015, 115, 12045; (c) Q. J. Wang, Y. Y. Su, L. X. Lia, and H. M. Huang, Chem. Soc. Rev., 2016, 45, 1257; (d) K. Hiraki, and T. Matsunaga, Organometallics, 1994, 13, 1878; (e) X.-S. Wu, Y. Chen, M.-B. Li, M.-G. Zhou, and S.-K. Tian, J. Am. Chem. Soc., 2012, 134, 14694; (f) B. M. Trost, M. Osipov, and G. Dong, J. Am. Chem. Soc., 2010, 132, 15800; (g) Y. Wang, J.-K. Xu, Y. Gu, and S.-K. Tian, Org. Chem. Front., 2014, 1, 812; (h) T.-T. Wang, F.-X. Wang, F.-L. Yang, and S.-K. Tian, Chem. Commun., 2014, 50, 3802.
- 9 (a) B. M. Trost, and M. D. Spagnol, J. Chem. Soc., Perkin Trans.
 1, 1995, 2083; (b) S. Mukherjee, and B. List, J. Am. Chem.
 Soc., 2007, 129, 11336; (c) X. Zhao, D. Liu, H. Guo, Y. Liu, and
 W. Zhang, J. Am. Chem. Soc., 2011, 133, 19354; (d) H. Yu, G.
 Zhang, Z. J. Liu, and H. M. Huang, RSC Adv., 2014, 4, 64235;

This journal is © The Royal Society of Chemistry 20xx

Journal Name

(e) H. Bricout, J.-F. Carpentier, and A. Mortreux, *Chem. Commun.*, 1997, 1393; (f) M. B. Li, Y. Wang, and S. K. Tian, *Angew. Chem. Int. Ed.*, 2012, **51**, 2968; (g) M. B. Li, H. Li, J. Wang, and C.-R. Liu, *Chem. Commun.*, 2013, **49**, 8190; (h) F. Garro-Helion, A. Merzouk, and F. Guibe, *J. Org. Chem.*, 1993, **58**, 6109; (k) X.-T. Ma, Y. Wang, R.-H. Dai, C.-R. Liu, and S.-K. Tian, *J. Org. Chem.*, 2013, **78**, 11071; (I) H. Yu, G. Zhang, Z. J. Liu, and H. M. Huang, *Angew. Chem. Int. Ed.*, 2015, **54**, 10912.

- 10 Q. Yu, L. Hu, Y. Wang, S. Zheng, and J. Huang, Angew. Chem. Int. Ed., 2015, 54, 15284.
- 11 V. Cadierno, S. E. García-Garrido, J. Gimeno, and N. Nebra, *Chem. Commun.*, 2005, 4086.
- 12 L. L. Zhang, L. H. Li, Y. Q. Wang, Y. F. Yang, X. Y. Liu, and Y. M. Liang, *Organometallics*, 2014, **33**, 1905.
- 13 (a) D. Zhao, J. H. Kim, L. Stegemann, C. A. Strassert, and F. Glorius, *Angew. Chem. Int. Ed.*, 2015, **54**, 4508; (b) A. J. Millett, A. Habtemariam, I. Romero-Canelon, G. J. Clarkson, and P. J. Sadler, *Organometallics*, 2015, **34**, 2683; (c) S. Wuebbolt, and M. Oestreich, *Angew. Chem. Int. Ed.*, 2015, **54**, 15876; (d) D. C. Powers, D. Y. Xiao, M. A. L. Geibel, and T. Ritter, *J. Am. Chem. Soc.*, 2010, **132**, 14530; (e) H. J. Tang, Y. H. Li, C. H. Wei, B. Chen, W. Yang, H. B. Wu, and Y. Cao, *Dyes Pigm.*, 2011, **91**, 413.
- 14 (a) S. O'Sullivan, E. Doni, T. Tuttle, and J. A. Murphy, *Angew. Chem. Int. Ed.*, 2014, **53**, 474; (b) P. Wipf, and P. Maciejewski, *Org. Lett.*, 2008, **10**, 4383; (c) S. Ghorpade, and R. S. Liu, *Angew. Chem. Int. Ed.*, 2014, **53**, 12885; (d) M. L. Wang, F. F. Xiao, Y. J. Bai, and X. D. Hu, *Synth. Commun.*, 2015, **45**, 2259.

Ruthenium-Catalyzed C-H Allylation of Arenes with Allylic Amines

Rui Yan and Zhong-Xia Wang*

The Ru-catalyzed pyridyl-directed C-H allylation of arenes with allylic amines was carried out in the presence of 5 mol % of $[Ru(p-cymene)Cl_2]_2$ and 0.5 equiv. of AgOAc in CF₃CH₂OH.

